Overview of trends in the control of cardiac arrhythmia: Past and future

American Journal of Cardiology

Volumn 84, Issue 9 SUPPL. 1, 1999, Pages 3-10

  Singh, Bramah N ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DOFETILIDE; DRONEDARONE; ERSENTILIDE; IBUTILIDE; METOPROLOL; SOTALOL; TEDISAMIL; TRECETILIDE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONFERENCE PAPER; DEFIBRILLATOR; DRUG INDICATION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HUMAN; IMPLANT; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUDDEN DEATH; SUPRAVENTRICULAR TACHYCARDIA;

EID: 0032745893     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00696-7     Document Type: Conference Paper

References (53)

1. Singh B.N. Antiarrhythmic drugs a re-orientation in light of recent developments in the control of disorders of rhythm . Am J Cardiol. 81:(suppl):1998;3D-13D.
2. Camm A.J., Zipes D.P. Antiarrhythmic drugs at the crossroads from the cell to the bedside . J Cardiovasc Electrophysiol. 10:1998;267-317.
3. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 337:1997;1576-1583.
4. Singh B.N. Expanding indications for the use of class III antiarrhythmic agents in patients at high risk for sudden death. J Cardiovasc Electrophysiol. 6:1995;887-900.
5. Preliminary Report effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction . N Engl J Med. 321:1989;406-412.
6. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 327:1992;227-233.
7. Singh BN. Rise and fall of guided antiarrhythmic therapy for ventricular tachycardia and fibrillation. J Cardiovasc Pharmacol Ther 1996;89-94.
8. Yusuf S., Teo K.K. Approaches to prevention of sudden death need for fundamental reevaluation . J Cardiovasc Electrophysiol. 2:1991;S233-S239.
9. Mason J.W. A randomized comparison of electrophysiologic study to electrocardiographic monitoring for prediction of antiarrhythmic drug efficacy in patients with ventricular tachyarrhythmias. N Engl J Med. 329:1993;445-451.
10. Mason J.W. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med. 329:1993;452-458.
11. The CASCADE Study randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle . Am J Cardiol. 72:1993;280-287.
12. Wever E.F., Hauer R.N., van Capelle F.L., Tijssen J.G., Crijns H.J., Algra A., Wiesfeld A.C., Bakker P.F., Robles de Medina E.O. Randomized study of implantable defibrillator as first-choice versus conventional strategy in postinfarct sudden death survivors. Circulation. 91:1995;2195-2203.
13. Kehoe R.F., Zheutlin T.A., Dunnington C.S., Mattioni T.A., Yu G., Spangenberg R.B. Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmias. Am Heart J. 65:(suppl):1990;58A-64A.
14. Singh B.N. Current antiarrhythmic drugs an overview of mechanisms of action and potential clinical utility . J Cardiovasc Electrophysiol. 10:1999;283-301.
15. Nasir N., Swarna U.S., Boahene K.A., Doyl T.K., Pacifico A. Therapy of sustained ventricular arrhythmias with amiodarone prediction of efficacy with serial electrophysiologic studies . J Cardiovasc Pharmacol Ther. 1:1996;123-133.
16. Connolly S.J., Gent M., Roberts R.S., Dorian P., Green M.S., Klein G.J., Mitchell L.B., Sheldon R.S., Roy D. Canadian Implantable Defibrillator Study (CIDS) study design and organization. CIDS Co-Investigators . Am J Cardiol. 72:(suppl F):1993;103F-108F.
17. Zipes D.P. An overview of arrhythmias and antiarrhythmic approaches. J Cardiovasc Electrophysiol. 10:1999;267-271.
18. st century . Am J Cardiol. 80:(suppl G):1997;99G-104G.
19. Singh BN. Antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias: the AVID trial. Commentary and reflections. In: Woosley RL and Singh SN, eds. Clinical Trials in Mortality Reduction in Patients with Cardiovascular Disease. New York: Marcel Dekker; 1999 (in press).
20. Hohnloser S.H. Implantable devices versus antiarrhythmic drug therapy. Am J Cardiol. 84:(suppl R):1999;56R-62R.
21. Leenen F.H.H. Cardiovascular consequences of sympathetic hyperactivity. Can J Cardiol. 15:(suppl A):1999;2A-12A.
22. Reiter M.J., Reiffel J.A. Importance of beta blockade in the therapy of serious ventricular arrhythmias. Am J Cardiol. 82:1998;91-99.
23. Boutitie F., Boissel J.P., Connolly S.J., Camm A.J., Cairns J.A., Julian D.G., Gent M., Janse M.J., Dorian P., Frangin G. Amiodarone interaction with beta-blockers analysis of the merged EMIAT and CAMIAT databases . Circulation. 99:1999;2268-2275.
24. Tonet J., Frank R., Fontaine G., Grosgogeat Y. Efficacy and safety of low doses of beta-blocker agents combined with amiodarone in refractory ventricular tachycardia. Pacing Clin Electrophysiol. 11:1988;1984-1989.
25. Julian D.G., Camm A.J., Frangin G., Janse M.J., Munoz A., Schwartz P.J., Simon P. Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction EMIAT . Lancet. 349:1997;667-673.
26. Cairns J.A., Connolly S.J., Roberts R.S., Gent M. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations CAMIAT . Lancet. 394:1997;675-682.
27. Effect of metoprolol CR/XL in chronic heart failure Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF) . Lancet. 353:1999;2001-2007.
28. The cardiac insufficiency bisoprolol study II (CIBIS II). Lancet. 353:1999;9-13.
29. Packer M., Bristow M.R., Cohn J.N. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
30. Teerlink J.R., Bassie B.M. Beta-adrenergic blocker mortality trials in congestive heart failure. Am J Cardiol. 84:(suppl R):1999;94R-102R.
31. Bardy G, Lee K, Mark D, Poole J, Fishbein D, Singh S, Troutman C, Christian V, Anderson J, Clapp-Channing N, Johnson G, for the SCD-HeFT Investigators. SCD-HeFT: prevention of sudden death in patients with congestive heart failure trial. In: Woosley RL and Singh SN, eds. Clinical Trials in Mortality Reduction in Patients with Cardiovascular Disease. New York: Marcel Dekker; 1999 (in press).
32. Wang Z.G., Pelletier L.C., Talajic M., Nattel S. Effects of flecainide and quinidine on human atrial potentials role of rate dependence and comparison with guinea pig, rabbit and dog tissues . Circulation. 82:1990;274-283.
33. Singh B.N. Sotalol current status and expanding indications . J Cardiovasc Pharmacol Ther. 4:1999;49-65.
34. Singh B.N. Antiarrhythmic actions of amiodarone a profile of a paradoxical agent . Am J Cardiol. 78:1996;41-53.
35. Kowey P.R., Marinchak R.A., Rials S.J., Bharucha D.B. Intravenous antiarrhythmic therapy in the acute control of in-hospital destabilizing ventricular tachycardia and fibrillation. Am J Cardiol. 84:(suppl R):1999;46R-51R.
36. Papp J.G., Nemeth M., Krassoi I., Mester L., Hala O., Varro A. Differential electrophysiologic effects of chronically administered amiodarone on canine Purkinje fibers versus ventricular muscle. J Pharmacol Exp Ther. 1:1996;287-296.
37. Sicouri S., Moro S., Litovsky S., Elizari M.V., Antzelevitch C. Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysiol. 8:1997;1269-1279.
38. Cui G., Sen L., Sager P.T., Uppal P., Singh B.N. Effects of amiodarone, sematilide and sotalol on QT dispersion. Am J Cardiol. 75:1995;465-469.
39. Sager P.T., Uppal P., Follmer C., Antimisiaris M., Pruitt C., Singh B.N. The frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation. 88:1993;1063-1068.
40. Kodama I., Kamiya K., Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res. 35:1997;13-29.
41. Hohnloser S., Klingenheben T., Singh B.N. Amiodarone-associated proarrhythmic effects a review with special reference to torsades de pointes tachycardia . Ann Intern Med. 121:1994;529-535.
42. Scheinman M.M., Levine J.H., Cannom D.S., Friehling T., Kopelman H.A., Chilson D.A., Platia E.V., Wilber D.J., Kowey P.R. A dose ranging study of intravenous amiodarone in patients with malignant ventricular tachycardias. Circulation. 92:1995;3264-3272.
43. Singh B.N., Vaughan Williams E.M. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol. 39:1970;657-667.
44. Latham K.R., Seletti D.F., Goldstein R.E. The effects of amiodarone and desethylamiodarone with solubilized nuclear thyroid hormone receptors. J Am Coll Cardiol. 7:1987;472-480.
45. Norman M.F., Lavin T.A. Competition of thyroid hormone action by amiodarone in rat pituitary tumor cells. J Clin Invest. 83:1989;306-313.
46. Hensley C.B., Bersohn M.M., Sarma J.S., Singh B.N., McDonough A.A. Amiodarone decreases Na,K-ATPase alpha 2 and beta 2 expression specifically in cardiac ventricle. J Mol Cell Cardiol. 26:1994;417-424.
47. 1-thyroid hormone receptor by amiodarone analogs. Endocrinology. 137:1996;2807-2814.
48. Polikar R., Burger A.G., Scherrer U., Nicod P. The thyroid and the heart. Circulation. 14:1993;184-193.
49. Manning A.S., Bruyninckx C., Ramboux J., Chatelain P. SR33589, a new amiodarone-like agent effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats . J Cardiovasc Pharmacol. 26:1995;453-461.
50. Manning A.S., Thisse V., Hodeige D., Chatelain P. SR33589, a new amiodarone-like antiarrhythmic agent electrophysiological effects in anesthetized dogs . J Cardiovasc Pharmacol. 25:1995;252-261.
51. Singh B.N., Nademanee K. Control of cardiac arrhythmias by selective lengthening of cardiac repolarization theoretical considerations and clinical observations . Am Heart J. 109:1985;421-430.
52. Sun W, Sarma JSM, Singh BN. Electrophysiologic effects of dronedarone (SR33589), a non-iodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation 1999 (in press).
53. Camm A.J., Yap G.Y. What should we expect from the next generation of antiarrhythmic drugs? J Cardiovasc Electrophysiol. 10:1999;307-317.